Search results
Results from the WOW.Com Content Network
Diabetic retinopathy (also known as diabetic eye disease) is a medical condition in which damage occurs to the retina due to diabetes.It is a leading cause of blindness in developed countries and one of the lead causes of sight loss in the world, even though there are many new therapies and improved treatments for helping people live with diabetes.
Intraretinal microvascular abnormalities (IRMA) are abnormalities of the blood vessels that supply the retina of the eye, a sign of diabetic retinopathy. [1] IRMA can be difficult to distinguish from and is likely a precursor to retinal neovascularization. One way to distinguish IRMA from retinal neovascularization is to perform fluorescein ...
Epiretinal membrane or macular pucker is a disease of the eye in response to changes in the vitreous humor or more rarely, diabetes.Sometimes, as a result of immune system response to protect the retina, cells converge in the macular area as the vitreous ages and pulls away in posterior vitreous detachment (PVD).
Proliferative vitreoretinopathy (PVR) is a disease that develops as a complication of rhegmatogenous retinal detachment.PVR occurs in about 8–10% of patients undergoing primary retinal detachment surgery and prevents the successful surgical repair of rhegmatogenous retinal detachment.
the 2007 finding that non-diabetic family members of type 1 diabetics had increased risk for microvascular complications, [62] such as diabetic retinopathy [63] Some genes appear to provide protection against diabetic complications, as seen in a subset of long-term diabetes type 1 survivors without complications. [64] [65]
There is an association between the grade of retinopathy and mortality. In a classic study in 1939 Keith and colleagues [6] described the prognosis of people with differing severity of retinopathy. They showed 70% of those with grade 1 retinopathy were alive after 3 years whereas only 6% of those with grade 4 survived.
Optometrists are trained and licensed to practice medicine for eye-related conditions (including bacterial/viral infections, inflammation, glaucoma, macular degeneration, and diabetic retinopathy). They can prescribe all topical medications (eye drops) and most oral medications (taken by mouth), including scheduled controlled substances.
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab.It is an anti-angiogenic [16] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.